NITRO-BID by Sanofi is clinical pharmacology: the principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Approved for angina pectoris due to coronary artery disease. First approved in 1982.
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
NITRO-BID is a nitroglycerin ointment formulation approved in 1982 for angina pectoris due to coronary artery disease. It works by relaxing vascular smooth muscle, dilating peripheral arteries and veins, and reducing cardiac preload and afterload. The drug is a small-molecule organic nitrate with a short serum half-life (~3 minutes) that requires drug-free intervals to prevent tolerance development.
Product approaching loss of exclusivity with minimal current Part D utilization (~21.6k claims in 2023), suggesting a mature, declining franchise with limited team expansion opportunities.
CLINICAL PHARMACOLOGY: The principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the…
Worked on NITRO-BID at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on NITRO-BID offers minimal career growth; with zero linked job openings and LOE approaching, the product is in managed decline rather than expansion mode. This role is best suited for professionals seeking stable, low-visibility work or those tasked with managing a mature franchise transition to generic competition.